11 Jan 2019 Research
Leukaemia: Investigating stem cells to prevent cancer
What is this research looking at?
The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.
Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.
Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.
I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.
What could this mean for people with leukaemia?
This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.
Related posts
17 October 2022
New campaign launches for the forgotten 500,000 families
Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…
4 April 2023
£200 grants for people affected by leukaemia once again available
Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…
31 October 2023
Chris Dew joins Leukaemia UK as Director of Finances & Resources
Leukaemia UK is delighted to announce the appointment of Chris Dew as Director of Finance & Resources, following ten years as Chief Financial Officer at musical therapy charity Nordoff-Robbins. The…
8 July 2025
The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care
The Best Practice Timed Pathway We’re delighted to share that Leukaemia UK, in partnership with Lymphoma Action and Myeloma UK, is working with the NHS England Cancer programme team to…